AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03255512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY1021189)
Description: 2.5 mg/tablet; 5 mg/tablet or 10 mg/tablet
Study NCT03255512 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT03255512 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isosorbide mononitrate (ISMN)
Description: 30 mg/tablet or 60 mg/tablet
Study NCT03255512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (ISMN)
Description: 30 mg/tablet or 60 mg/tablet
Study NCT01693627 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pinnacle/Corail with collar
Description: Uncemented THA using Pinnacle-100/Marathon XLPE(Depuy, Warsaw, IN) acetabular component and Corail(Depuy,Warsaw,IN)collared femoral stem with 32mm Alumina Biolox Forte(Depuy,Warsaw,IN). Tantalum beads will be inserted into periprosthetic bone.
Study NCT01693627 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Marathon/Corail with collar
Description: Reversed hybrid THA using cemented Marathon XLPE(Depuy,Warsaw,IN) acetabular component and an uncemented Corail(Depuy,Warsaw,IN)collared femoral component with 32 mm Alumina Biolox Forte(Depuy,Warsaw,IN)head. Tantalum beads will be inserted into periprosthetic bone.
Study NCT01693627 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pinnacle/Corail without collar
Description: Uncemented THA using Pinnacle-100/Marathon XLPE(Depuy, Warsaw, IN) acetabular component and Corail(Depuy,Warsaw,IN)collarless femoral stem with 32mm Alumina Biolox Forte(Depuy,Warsaw,IN). Tantalum beads will be inserted into periprosthetic bone.
Study NCT01693627 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Marathon/Corail without collar
Description: Reversed hybrid total hip arthroplasty using cemented Marathon XLPE(Depuy,Warsaw,IN) acetabular component and an uncemented Corail(Depuy,Warsaw,IN)collarless femoral component with 32 mm Alumina Biolox Forte(Depuy,Warsaw,IN)head. Tantalum beads will be inserted into periprosthetic bone.
Study NCT01746264 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D 3 at 100,000 IU once a month for 3 months
Study NCT01509742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Single dose of 7.5 mcg/kg, injected subcutaneously followed by a hypoglycaemic clamp by concentration measurement
Study NCT01509742 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Single dose injected subcutaneously followed by a hypoglycaemic clamp by concentration measurement
Study NCT03734211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: 420 mg evolocumab will be administered subcutaneously by giving 3 injections consecutively within 30 minutes using the single-use prefilled autoinjector.
Study NCT03734211 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously by giving 3 injections consecutively within 30 minutes using the single-use prefilled autoinjector.
Study NCT03344926 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACTsmart
Description: Participant receive ACT treatment via a smart phone application, including psychologist support via a message function within the application.~Treatment content is divided into four modules:~1. education about pain behaviors, exposure and acceptance and commitment therapy~2. education about pain physiology~3. exercises on changing behaviors, acceptance, mindfulness, defusion and exposure~4. value based exposure in the participant's daily life
Study NCT03939325 — intervention group
Intervention type: RADIATION
Intervention: ESWL
Description: The impact of different frequencies on pattern of disintegration of renal stones
Study NCT02299817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: Prolia is used to treat osteoporosis (a disease that makes bones fragile) in women who have been through the menopause and in men who have an increased risk of fracture (broken bones). In women who have been through the menopause Prolia reduces the risk of fractures in the spine and elsewhere in the body, including in the hip.~Prolia is also used to treat bone loss in men receiving treatment for prostate cancer that increases their risk of fracture. Prolia reduces the risk of fractures in the spine.~Recently denosumab was found to be effective in preventing osteoporosis related fractures in post-menopausal women by blocking RANKL and thereby inhibiting the development and activity of osteoclast.
Study NCT02299817 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03334721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: 5 day trial of gabapentin with titration to 1,200mg
Study NCT03334721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Capsule
Description: 5 day trial of matched placebo
Study NCT03858166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Description: 6mg PEG-rhG-CSF was administrated subcutaneously at different time after chemotherapy.
Study NCT03858166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-rhG-CSF
Description: 6mg PEG-rhG-CSF was administrated subcutaneously at different time after chemotherapy.
Study NCT01859806 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreaticogastrostomy group
Description: Standard PD with regional lymphadenectomy was performed. PG was done between pancreatic stump and posterior surface of the stomach with 2 layer interrupted anastomosis,and duct to mucosa.
Study NCT01859806 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Isolated Roux PJ group
Description: Isolated Roux PJ group, reconstruction was begun using the transected jejunum and ,which was anastomosed in end to side fashion. A separate Roux loop was performed for HJ, by dividing the jejunum about 40 cm beyond the pancreatic anastomosis and GJ was done in this loop (30 cm caudally from HJ). The PJ loop was anastomosed to the main loop (20 cm caudal to GJ).
Study NCT03203135 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional prevention programme
Description: The nutritional prevention programme will offer a wide range of food and physical activity activities adapted to the life of the company (example: culinary demonstration, physical activity, provision of fruit baskets, etc.) .
Study NCT04216758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Patients firstly receive nab-paclitaxel 100 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
Study NCT04216758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Patients receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
Study NCT04216758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tegafur
Description: Patients secondly receive tegafur Body surface area \< 1.25 m\^2, 60 mg/d;Body surface area ≥ 1.25 m\^2 to \< 1.5 m\^2, 80 mg/d;Body surface area ≥ 1.5 m\^2, 100 mg/d (po) on days 1-21 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
Study NCT02238483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7624 1.0 mg
Description: Inhaled AZD7624 solution, 11 mg/mL
Study NCT00982449 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FIAU-PET-CT-2
Description: 1-3 days after chemotherapy, subject get I-FIAU 2 mCi, then have FIAU-PET-CT done 2 - 4 hours after I-FIAU
Study NCT00982449 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FIAU-PET-CT-4
Description: 1-3 days after any chemotherapy that may activate viral TK, 4 mCi, rather than 2 mCi, of I-FIAU are administered, followed 2 - 4 hours later by FIAU-PET-CT
Study NCT01880125 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tramadol HCI/Acetaminophen
Description: Test drug: Tramadol HCI/Acetaminophen 75/650mg, two times daily. Reference drug: Tramadol HCI/Acetaminophen 37.5/325 mg, four times daily.
Study NCT02238483 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled placebo solution
Study NCT03476811 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.25% Marcaine at 2ml/hr and pain medications
Description: Subcutaneous pain control with OnQ Subcutaneous Drug pump
Study NCT03476811 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placement of OnQ Drug pump
Description: Subcutaneous placement of OnQ drug pump with normal saline infusion
Study NCT02574455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Description: 10 mg/kg administered as a slow intravenous (IV) infusion either by gravity or with an infusion pump. Infusion rate for the first 15 minutes will start with 50 mg/hour or less with a subsequent infusion of 100 to 200 mg/hour up to a maximum recommended rate (advanced every 15 to 30 minutes) of 500 mg/hour with a subsequent infusion of 1000 mg/hour.
Study NCT02574455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin
Description: Administered IV over 2 to 5 minutes at a dose 1.4 mg/m\^2 at North American sites and 1.23 mg/m\^2 at European sites on Days 1 and 8 of a 21-day cycle for up to 15.3 months. Lower doses will be administered on the same schedule to participants with moderate hepatic impairment (ie, Child-Pugh B; 0.7 mg/m\^2 and 0.67 mg/m\^2 for North American and European sites, respectively).
Study NCT02574455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1000 to 1250 mg/m\^2 will be administered in a 21-day cycle, with capecitabine administered orally twice daily for 2 weeks followed by 1-week rest period for up to 10.6 months.
Study NCT02574455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 800 to 1200 mg/m\^2 will be administered IV over 30 minutes on Days 1, 8, and 15 of a 28-day cycle for up to 8.1 months.
Study NCT02574455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: 25 mg/m\^2 will be administered as a weekly IV injection over 6-10 minutes for up to 11.5 months. Vinorelbine will not be allowed as TPC for any participant with Grade 2 neuropathy.
Study NCT03199209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral, Psychological or Informational Intervention
Description: Receive information about healthy lifestyles
Study NCT03199209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral, Psychological or Informational Intervention
Description: Receive information about healthy homes
Study NCT03199209 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Visit
Description: Attend study visit with research staff
Study NCT03199209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03199209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message
Description: Receive information about healthy lifestyles
Study NCT03199209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message
Description: Receive texts about healthy homes
Study NCT01655888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab is administered as endovenous infusion
Study NCT04718688 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CO-OP rehabilitation
Description: The intervention was included within the child's conventional rehabilitation program.~In the CO-OP original protocol, the child sets 3 goals. Here, we concentrated on two rather than three goals, as addressing three occupations per session seemed too ambitious given the children's cognitive profile (the third goal served as control goal).~We chose to increase the number of sessions to 14 (two sessions per week for seven weeks, vs ten in the original protocol).~The global strategy was taught to the child at the first session. The following sessions consisted of an iterative process of implementation of the global strategy in the context of guided discovery to identify domain specific strategies to overcome performance ''breakdowns the children were experiencing when performing the self-selected tasks. In addition, homework was assigned to encourage the application and practice. Parents were invited to attend the sessions if it was possible for them.
Study NCT01186198 — intervention group
Intervention type: DEVICE
Intervention: MINI TREK RX 1.20 mm Coronary Dilatation Catheter
Description: Enlarging coronary luminal diameter during percutaneous coronary intervention (PCI) procedures in subjects with ischemic heart disease due to stenotic lesions
Study NCT02206269 — intervention group
Intervention type: DEVICE
Intervention: Alair System
Description: The Alair system is used for doing bronchial thermoplasty.
Study NCT04982536 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VMCore Biopsy System
Description: Prostate Examine
Study NCT00645918 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: clopidogrel
Description: oral, 75 mg daily for 6 months starting on day of randomization
Study NCT00645918 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral, 6 pill loading dose on day of randomization; one pill daily for 6 months starting on day of randomization
Study NCT04982536 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Biopsy Needle
Description: Prostate Examine
Study NCT01514344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intralesional rituximab
Description: 10-20 mg (1-2 ml) rituximab once a week for 4 weeks; followed by 10-20 mg (1-2 ml) rituximab monthly per six months
Study NCT01514344 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: supplemental autologous serum
Description: patients in PD or SD during or after administration of 6 doses monthly rituximab will be administered the same dose of intralesional rituximab supplemented by autologous serum
Study NCT02120222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selinexor
Description: Given PO
Study NCT02120222 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Correlative studies
Description: Blood will be collected for pK and pDn analysis pretreatment on day 1 and 8 hours after treatment, on day 1 of cycles 1 and 2.
Study NCT02570022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Local infiltration of liposomal bupivacaine
Study NCT02570022 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inter-scalene nerve block
Description: Pre-operative inter-scalene nerve block
Study NCT02570022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ropivicaine was used for the inter-scalene nerve block.
Study NCT01070069 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEVAR (ProGlide closure)
Description: Percutaneous EVAR facilitated by the ProGlide closure device
Study NCT01070069 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SEVAR (IntuiTrak)
Description: Standard vascular exposure for access prior to EVAR
Study NCT01070069 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEVAR (Prostar XL closure)
Description: Percutaneous EVAR facilitated by the Prostar XL closure device
Study NCT04110223 — intervention group
Intervention type: GENETIC
Intervention: next generation sequence
Description: targeted NGS of patients' pretreatment tumor biopsy samples using a 474-gene panel, which covers cancer- and radio-sensitivity-related mutations and SNPs.
Study NCT00645918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: oral, 450 mg loading dose on day of randomization; 75 mg daily for 6 months starting on day of randomization
Study NCT01079286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir and temsirolimus
Description: Nelfinavir tablets of 250mg given twice daily in an escalating dosis schedule, Temsirolimus i.v. given weekly in an escalating dosis schedule
Study NCT01360762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentamidine
Description: Pentamidine isethionate 300 mg for one vial for intramuscular or intravenous route(1 mg of pentamidine isethionate is equivalent to 0.57 mg of pentamidine base)
Study NCT03534726 — intervention group
Intervention type: DEVICE
Intervention: 7 T CMR
Description: 7 tesla MRI device
Study NCT01610453 — intervention group
Intervention type: PROCEDURE
Intervention: ultrasound examination
Description: transabdominal and transperineal ultrasound examinations
Study NCT03234894 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SiteSeal Endovascular
Description: to evaluate the safety of the SiteSeal™ Endovascular Adjunctive Compression Device across a broad array of patients undergoing interventional endovascular procedures.
Study NCT04385056 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSCTC-0010
Description: MSCTC-0010 is a suspension product for infusion. The active ingredient is the umbilical cord-derived allogeneic mesenchymal stem cells (US-MSCs).
Study NCT00462358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-520, KSP(Eg5) inhibitor; intravenous
Description: Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
Study NCT00462358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
Description: Part 1: standard of care; Part 2: standard of care.
Study NCT01306786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quadruple therapy
Description: First line: 5 days esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d.~Cross over second line for those who failed first line: 7 days esomeprazole 20mg b.d., amoxicillin 1g b.d. and clarithromycin 500mg b.d
Study NCT01306786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triple therapy
Description: First line: 7 days esomeprazole 20mg b.d., amoxicillin 1g b.d. and clarithromycin 500mg b.d Second line cross over if failed first line: 7 days quadruple therapy: esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d.)
Study NCT02729506 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transarterial Radioembolization
Description: Yttrium-90 radioembolization (90Y) is a relatively new technique involving the trans-arterial administration of glass or resin microspheres loaded with Yttrium-90, a β-emitting isotope, delivering selective internal radiation to the tumor.
Study NCT02729506 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transarterial Chemoembolization using drug-eluting beads
Description: TACE is a procedure in which a catheter is introduced into the branches of the hepatic artery supplying the tumor. Embolic material and chemotherapeutic agents are deployed through the catheter directly into the tumor vasculature. This technique potentially enhances the cytotoxic effect by inducing ischemia and retention of the therapeutic agent in the vicinity of the tumor.~The drug-eluting beads (DEBs) enable standardization of TACE since DEBs act as both an occluding agent as well as a drug-loaded carrier, achieving local ischemia and cytotoxic death of the tumor with one device.
Study NCT04092231 — intervention group
Intervention type: BEHAVIORAL
Intervention: Early speech perception test
Description: The early speech test is one of the closed-set response speech discrimination tests,using object identification technique.It was carefully designed for estimation of speech perception abilities in very young children who have extremely low verbal abilities
Study NCT01084707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Nicotine
Description: Oral Nicotine either self-administered or provided by study personnel within 12 hours
Study NCT01084707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Lozenge
Description: Nicotine lozenge marketed as NiQuitin™ 4 mg hourly within 12 hours
Study NCT01084707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine gum
Description: Nicotine gum marketed as Nicorette® 4 mg hourly within 12 hours
Study NCT01137708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethinyloestradiol (EE) and levonorgestrel (LN), CP-690,550 + ethinyloestradiol (EE) and levonorgestrel (LN)
Description: Period 1: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel alone Period 2: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel plus 30 mg CP-690,550 after 9 days of CP-690,550 at 30 mg BID
Study NCT01137708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550 + ethinyloestradiol (EE) and levonorgestrel (LN), ethinyloestradiol (EE) and levonorgestrel (LN)
Description: Period 1: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel plus 30 mg CP-690,550 after 9 days of CP-690,550 at 30 mg BID Period 2: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel alone
Study NCT04992364 — intervention group
Intervention type: OTHER
Intervention: Burnout and Clinical performances questionnaires
Description: Subjects were given questionnaires to assess burnout score and clinical performances